Navigation Links
Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
Date:10/30/2013

EXTON, Pa., Oct. 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. rheumatologists are moderately satisfied with the currently available biologic agents as well as Pfizer's Xeljanz for the treatment of rheumatoid arthritis (RA). Physicians have a strong preference for the more established, market-leading TNF-alpha inhibitors, Amgen/Pfizer's Enbrel and AbbVie's Humira, over other biologic agents and Xeljanz.  Surveyed physicians rated Enbrel and Humira highest in product satisfaction, perceive these agents as having the most favorable benefit/risk profiles, and they indicate that both products outperform other TNF-alpha inhibitors on the most important stated attributes to prescribing RA therapies. Consequently, these two biologic therapies are used typically as first- or second-line biologic treatment after conventional disease-modifying antirheumatic drug (DMARD) therapy failure.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The TreatmentTrends®:Rheumatoid Arthritis (US) report finds that rheumatologists participating in this study also rated Xeljanz, the newest entrant in the RA market, moderately. However, Xeljanz was rated significantly lower than all biologics on overall product performance. In addition, Xeljanz has yet to carve out a distinct place in the RA treatment algorithm. Physicians reported using the product most often after one to three TNF-alpha inhibitor failures. The report also finds that only 14 percent of Xeljanz patients were biologic naive.

"Xeljanz was on the market 9 months at the time this study was fielded, so rheumatologists may not be certain as to which patient types would benefit most from Xeljanz, which is why they are trying it on different patient types at various points in the treatment algorithm," said BioTrends Senior Director Greta Unger. "A relatively low percentage of Xeljanz patients were biologic naive even though it has been approved for use in this patient group. It will be interesting to see if physicians' behavior changes over time as they gain more experience with the product."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
2. At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
3. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
4. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
5. Surveyed U.S. Neurologists Report Greater Overall Satisfaction with Tecfidera than with Platform Injectables and Other Oral Multiple Sclerosis Therapies
6. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
7. A Significant Share of Surveyed Treatment-Naive and Prior Failure HCV Patients Plan to Initiate an HCV Treatment Regimen in the Next Year
8. Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idecs Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
9. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
10. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
11. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... Jan. 14, 2017  Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... According ...
(Date:1/13/2017)... -- Eli Lilly and Company (NYSE: LLY ... announced today that the U.S. Food and Drug Administration ... drug application (NDA) for investigational baricitinib, a once-daily oral ... arthritis (RA). The NDA for baricitinib was submitted to ... extended the action date to allow time to review ...
(Date:1/13/2017)... York , January 13, 2017 ... prevalence of AIDS will collectively contribute to the demand for ... to reach a value of US$ 551.0 Mn by 2016 ... will remain the most lucrative markets for western blotting, whereas ... the market globally. ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... ... Louisans are well-aware of the following facts at present:, Flu ... having no effect on keeping this particularly bad strain of the flu away , ... or sniffling , These facts are well-known among the team at Woodard! ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... San Francisco ... iTero Element, the latest in 3-D scanning device which is capable of taking digital ... latest advances in dentistry, such as CAD CAM restorations , in terms of ...
(Date:1/15/2017)... Cary, NC (PRWEB) , ... January 15, 2017 , ... Whole Health Supply, LLC is ... CP-140L . There are also new avenues for purchase. , The 2017 edition has ... can cause issues for the older boomers as well as diabetics. This handle is reinforced ...
(Date:1/15/2017)... ... January 15, 2017 , ... The Gravity Vault Indoor ... Radnor, Pennsylvania. As construction wraps up on the 14,000+ square foot climbing gym, the ... sixth location, including three in New Jersey and two in New York. With this ...
(Date:1/14/2017)... ... January 14, 2017 , ... "TransFreeze Volume 3 is a self animating masking transition ... in Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... freeze frame transition from one clip to the next. , To use “Cut-Out ...
Breaking Medicine News(10 mins):